Please login to the form below

Not currently logged in

Merck & Co enters $430m diabetes deal with Abide

Will target group of enzymes known as serine hydrolases

Merck and Co - US headquarters

Merck & Co has expanded its efforts to research new diabetes treatments, signing a new partnership with California-based biopharma Abide Therapeutics.

Worth $430m in upfront, funding and milestone payments, the deal covers three targets identified by Abide as potential targets for therapies in type 2 diabetes for which Merck will gain worldwide commercial rights.

These targets are part of a group of enzymes know as serine hydrolases, which Abide says have potential in the treatment of metabolic conditions, such as diabetes.

There are some 200 human serine hydrolases, but most are poorly categorised and the group has remained largely unexplored as drug targets.

Merck's large fee demonstrates some level of confidence in their potential in diabetes - an increasingly competitive market as levels increase across the world.

The unique enzyme-based method of treatment offered by Abide will also be attractive to Merck, with several diabetes products facing stricter regulation and tough approval processes due to increased concerns about their cardiovascular safety.

The deal comes just days after Merck announced it would collaborate with Pfizer on phase III diabetes compound ertugliflozin.

The sodium glucose co-transporter (SGLT2) inhibitor was originality developed by Pfizer and now a Merck subsidiary will work alongside it on in late development and helping to commercialise ertugliflozin if it is approved.

One of the key reason for the Pfizer deal is the potential to combine ertugliflozin with Merck's DPP-4 inhibitor Januvia (sitagliptin).

Merck also has a Januvia follow-up in development, with phase IIb data suggesting that MK-3102 could offer a similar level of effectiveness, but at a once-weekly rather than once-daily dosage.

3rd May 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....